Sharenet Sites 
Sharenet Sites
TR-1: Standard form for notification of major holdings
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
("Mediclinic", the "Company", or the "Group")
9 September 2021
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft
Word format if possible)
1a. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are MEDICLINIC INTERNATIONAL PLC
attached:
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify):
3. Details of person subject to the notification obligation
Name PUBLIC INVESTMENT CORPORATION SOC LIMITED
City and country of registered office (if applicable) PRETORIA, SOUTH AFRICA
4. Full name of shareholder(s) (if different from 3.)
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or
08/09/2021
reached:
6. Date on which issuer notified (DD/MM/YYYY): 09/09/2021
7. Total positions of person(s) subject to the notification obligation
% of voting rights % of voting rights Total number of
attached to shares through financial Total of both in % voting rights of
(total of 8. A) instruments (8.A + 8.B) issuer
(total of 8.B 1 + 8.B 2)
Resulting situation
on the date on which
threshold was
crossed or reached 9.982%. 9.982%. 737 243 810
Position of previous
notification (if 10.009% 10.009%
applicable)
8. Notified details of the resulting situation on the date on which the threshold was crossed or
reached
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares
ISIN code (if possible) Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive
2004/109/EC) (DTR5.1) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.2.1) (DTR5.2.1)
Ordinary Shares
73 594 271 9.982%.
ISIN: GB00B8HX8Z88
SUBTOTAL 8. A 73 594 271 9.982%.
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Number of voting rights
Type of financial Expiration Exercise/ that may be acquired if
% of voting rights
instrument date Conversion Period the instrument is
exercised/converted.
SUBTOTAL 8. B 1 NIL NIL
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive
2004/109/EC (DTR5.3.1.1 (b))
Exercise/ Physical or
Type of financial Expiration Number of
Conversion cash % of voting rights
instrument date voting rights
Period settlement
SUBTOTAL
8.B.2 NIL NIL
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not
control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity X
(please add additional rows as necessary)
% of voting rights
% of voting rights if it Total of both if it
through financial
equals or is higher equals or is higher
Name instruments if it equals
than the notifiable than the notifiable
or is higher than the
threshold threshold
notifiable threshold
PUBLIC INVESTMENT
CORPORATION SOC 9.982%. 9.982%.
LIMITED
10. In case of proxy voting, please identify:
Name of the proxy holder N/A
The number and % of voting rights held N/A
The date until which the voting rights will be held N/A
11. Additional information
Name: REITUMETSE KAU
E-Mail: Reitumetse.Kau@pic.gov.za
TEL: 0127423747
Place of completion PRETORIA, SOUTH AFRICA
Date of completion 09 September 2021
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with
divisions in Switzerland, Southern Africa (South Africa and Namibia) and the UAE.
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in
such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by
patients, medical practitioners, funders and regulators of healthcare in each of its markets.
At 30 June 2021, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health facilities, 18 day
case clinics and 18 outpatient clinics. Hirslanden operated 17 hospitals and four day case clinics in Switzerland
with more than 1 900 inpatient beds; Mediclinic Southern Africa operations included 50 hospitals (three of which in
Namibia), five sub-acute hospitals, two mental health facilities and 12 day case clinics (four of which operated by
Intercare) across South Africa, and around 8 600 inpatient beds; and Mediclinic Middle East operated seven
hospitals, two day case clinics and 18 outpatient clinics with more than 900 inpatient beds in the UAE. In addition,
under management contracts, Mediclinic Middle East operates one hospital in Abu Dhabi and will open a 200-bed
hospital in the Kingdom of Saudi Arabia in mid-2022.
The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with secondary
listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in
the United Kingdom and listed on the LSE.
For further information, please contact:
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 09-09-2021 01:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
